![](/img/cover-not-exists.png)
Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP
John F. DiJoseph, Maureen M. Dougher, Deborah Y. Evans, Bin-Bing Zhou, Nitin K. DamleVolume:
67
Language:
english
Pages:
9
DOI:
10.1007/s00280-010-1342-9
Date:
April, 2011
File:
PDF, 561 KB
english, 2011